Insilico Medicine nominates ISM1745 as preclinical candidate for MTAP-deleted cancers
Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced the nomination of ISM1745, a potentially best-in-class MTA cooperative…
Read More...
Read More...